Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a leader in the development of next-generation mental health treatments, has announced that its CEO, Doug Drysdale, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. Scheduled for August 12, 2025, in Boston, this event will spotlight Cybin's pioneering work in neuropsychiatry, particularly its efforts to address the significant unmet needs in mental health care.
The presentation, which will be webcast live at 2:30 p.m. ET, offers investors and the public a unique opportunity to learn about Cybin's clinical-stage treatments, including CYB003 and CYB004. These proprietary compounds are currently under investigation for their potential to treat major depressive disorder and generalized anxiety disorder, respectively. The archived version of the webcast will be available on Cybin's investor relations site, providing ongoing access to this valuable information.
Cybin's commitment to revolutionizing mental health care through innovative treatments is more than just a corporate mission; it represents a beacon of hope for millions worldwide suffering from mental health conditions. The company's focus on developing intermittent treatments that offer long-lasting results could significantly alter the current treatment paradigm, which often relies on daily medications with varying degrees of efficacy and side effects.
For those interested in following Cybin's progress or learning more about its research pipeline, additional information can be found on the company's website at https://www.cybin.com. Updates and news relating to Cybin are also available in the company's newsroom at https://ibn.fm/CYBN.
This presentation at the Canaccord Genuity Growth Conference is not just a routine corporate engagement; it's a pivotal moment for Cybin to showcase its potential to transform mental health treatment. With mental health issues on the rise globally, the implications of Cybin's work extend far beyond the pharmaceutical industry, offering hope for a future where mental health conditions are treated more effectively and with fewer side effects.
